Pell Bio-Med Technology Co Ltd Sustainability Reports
The company specializes in the research and development of cellular gene therapies, focusing primarily on advanced chimeric antigen receptor T-cell (CAR-T) immunotherapies for cancer treatment. It also provides non-genetically modified cell therapy products, including cytokine-induced killer cells and adipose-derived stem cell treatments.
Sector: Manufacturing
Country: Taiwan
Exchange: Taiwan Stock Exchange
FIGI: BBG01LTL85Q6
2 reports from 2023 to 2024
